tiprankstipranks
Advertisement
Advertisement

OTLK Stock Latest News

Regulatory Uncertainty and Data Limitations Justify Hold Rating and Constrained Upside for Outlook Therapeutics
RatingsRegulatory Uncertainty and Data Limitations Justify Hold Rating and Constrained Upside for Outlook Therapeutics
1d ago
OTLK
Outlook Therapeutics Pursues FDA Dispute Resolution for ONS-5010
PremiumCompany Announcements
Outlook Therapeutics Pursues FDA Dispute Resolution for ONS-5010
2d ago
8K
OTLK
Outlook Therapeutics submits formal dispute resolution request to FDA
PremiumThe Fly
Outlook Therapeutics submits formal dispute resolution request to FDA
2d ago
OTLK
Outlook Therapeutics Completes Dilutive Equity Offering With Warrants
PremiumCompany Announcements
Outlook Therapeutics Completes Dilutive Equity Offering With Warrants
15d ago
8K
OTLK
Outlook Therapeutics announces common stock, warrant offering, no amount given
PremiumThe Fly
Outlook Therapeutics announces common stock, warrant offering, no amount given
17d ago
OTLK
Outlook Therapeutics Refinances Debt, Extends Note Maturities
PremiumCompany AnnouncementsOutlook Therapeutics Refinances Debt, Extends Note Maturities
24d ago
8K
OTLK
Outlook Therapeutics announces $18.4M non-convertible note financing
Premium
The Fly
Outlook Therapeutics announces $18.4M non-convertible note financing
24d ago
OTLK
Outlook Therapeutics Announces Board Resignation and Size Reduction
Premium
Company Announcements
Outlook Therapeutics Announces Board Resignation and Size Reduction
29d ago
8K
OTLK
Outlook Therapeutics price target lowered to $6 from $10 at Ascendiant
PremiumThe Fly
Outlook Therapeutics price target lowered to $6 from $10 at Ascendiant
29d ago
OTLK
Outlook Therapeutics Shareholders Back Board, Pay, and Auditor
PremiumCompany Announcements
Outlook Therapeutics Shareholders Back Board, Pay, and Auditor
30d ago
8K
OTLK
Outlook Therapeutics advances FDA dialogue on ONS-5010 approval
PremiumCompany Announcements
Outlook Therapeutics advances FDA dialogue on ONS-5010 approval
1M ago
8K
OTLK
Outlook Therapeutics provides update following FDA meeting on ONS-5010
PremiumThe Fly
Outlook Therapeutics provides update following FDA meeting on ONS-5010
1M ago
OTLK
Outlook enters distribution agreement for sale of Lytenava in Switzerland
PremiumThe FlyOutlook enters distribution agreement for sale of Lytenava in Switzerland
2M ago
OTLK
Outlook Therapeutics Faces Nasdaq Minimum Bid Price Noncompliance
Premium
Company Announcements
Outlook Therapeutics Faces Nasdaq Minimum Bid Price Noncompliance
2M ago
8K
OTLK
Neutral Outlook Maintained Amid Slower Lytenava Ramp and Heightened U.S. Regulatory and Market Risks for ONS-5010
Premium
Ratings
Neutral Outlook Maintained Amid Slower Lytenava Ramp and Heightened U.S. Regulatory and Market Risks for ONS-5010
2M ago
OTLK
Outlook Therapeutics reports adjusted Q1 EPS (22c), consensus (17c)
PremiumThe Fly
Outlook Therapeutics reports adjusted Q1 EPS (22c), consensus (17c)
2M ago
OTLK
Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA
PremiumCompany Announcements
Outlook Therapeutics Seeks FDA Meeting on ONS-5010 BLA
2M ago
8K
OTLK
Outlook Therapeutics sumbits Type A meeting request to FDA
PremiumThe Fly
Outlook Therapeutics sumbits Type A meeting request to FDA
2M ago
OTLK
OTLK Earnings this Week: How Will it Perform?
PremiumPre-Earnings
OTLK Earnings this Week: How Will it Perform?
2M ago
OTLK
Largest borrow rate increases among liquid names
PremiumThe FlyLargest borrow rate increases among liquid names
3M ago
EC
KDK
Outlook Therapeutics appoints Laura Cantrell as VP, corporate strategy
Premium
The Fly
Outlook Therapeutics appoints Laura Cantrell as VP, corporate strategy
3M ago
OTLK
Largest borrow rate increases among liquid names
Premium
The Fly
Largest borrow rate increases among liquid names
3M ago
NFE
USO

Trending

Name
Price
Price Change
SPX
S&P 500
―
DJIA
Dow Jones
―
NDX
Nasdaq 100
―
More Trending Stocks >